Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. II. Agonist and Antagonist Properties at Subtypes of Dopamine D2-Like Receptor and α1/α2-Adrenoceptor
@article{NewmanTancredi2002DifferentialAO, title={Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. II. Agonist and Antagonist Properties at Subtypes of Dopamine D2-Like Receptor and $\alpha$1/$\alpha$2-Adrenoceptor}, author={Adrian Newman-Tancredi and Didier Cussac and Valérie Audinot and Jean Paul Nicolas and Fr{\'e}d{\'e}ric De Ceuninck and Jean A. Boutin and Mark J Millan}, journal={Journal of Pharmacology and Experimental Therapeutics}, year={2002}, volume={303}, pages={805 - 814} }
The accompanying multivariate analysis of the binding profiles of antiparkinson agents revealed contrasting patterns of affinities at diverse classes of monoaminergic receptor. Herein, we characterized efficacies at human (h)D2SHORT(S), hD2LONG(L), hD3, and hD4.4receptors and at hα2A-, hα2B-, hα2C-, and hα1A-adrenoceptors (ARs). As determined by guanosine 5′-O-(3-[35S]thio)triphosphate ([35S]GTPγS) binding, no ligand displayed “full” efficacy relative to dopamine (100%) at all “D2-like” sites…
159 Citations
Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. III. Agonist and Antagonist Properties at Serotonin, 5-HT1 and 5-HT2, Receptor Subtypes
- BiologyJournal of Pharmacology and Experimental Therapeutics
- 2002
Antiparkinson agents display markedly different patterns of agonist and antagonist properties at multiple 5-HT receptor subtypes, although all show modest (agonist) activity at5-HT1A sites, and their contrasting actions at 5-ht2A and 5- HT2C sites may be of particular significance to their functional profiles in vivo.
Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor Subtypes
- BiologyJournal of Pharmacology and Experimental Therapeutics
- 2002
An innovative multivariate analysis revealed marked heterogeneity in binding profiles of antiparkinson agents at diverse receptors implicated in the etiology and/or treatment of Parkinson's disease.
Pharmacological Profile of 2-Bromoterguride at Human Dopamine D2, Porcine Serotonin 5-Hydroxytryptamine 2A, and α2C-Adrenergic Receptors, and Its Antipsychotic-Like Effects in Rats
- Biology, PsychologyThe Journal of Pharmacology and Experimental Therapeutics
- 2013
2-bromoterguride may be a strong candidate for the treatment of schizophrenia with a lower risk to induce EPS because of its in vitro and in vivo properties.
Interaction of the preferential D3 agonist (+)PHNO with dopamine D3-D2 receptor heterodimers and diverse classes of monoamine receptors: Relevance for PET imaging.
- Biology, MedicineEuropean journal of pharmacology
- 2022
Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors
- Psychology, BiologyPsychopharmacology
- 2006
The antiparkinson agent, S32504, displays DS properties principally mediated by high-efficacy activation of D2 receptors Antipsychotics known to act as partial agonists at D2/D3 receptors attenuate DS properties of S32 504, actions reflecting their low efficacy at these sites.
Differential induction of adenylyl cyclase supersensitivity by antiparkinson drugs acting as agonists at dopamine D1/D2/D3 receptors vs D2/D3 receptors only: Parallel observations from co-transfected human and native cerebral receptors
- Biology, PsychologyNeuropharmacology
- 2011
From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease.
- Biology, PsychologyPharmacology & therapeutics
- 2010
Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole
- Biology, ChemistryExperimental Neurology
- 2003
S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: II. Actions in Rodent, Primate, and Cellular Models of Antiparkinsonian Activity in Comparison to Ropinirole
- Biology, ChemistryJournal of Pharmacology and Experimental Therapeutics
- 2004
S32504 displays potent and stereospecific activity in rodent, primate, and cellular models of antiparkinsonian properties and engagement of D3 receptors contributes to its neuroprotective properties.
Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors
- Psychology, BiologyBehavioural pharmacology
- 2006
The dopamine D2/D3 receptor agonist and &agr;2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of…
References
SHOWING 1-10 OF 50 REFERENCES
Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor Subtypes
- BiologyJournal of Pharmacology and Experimental Therapeutics
- 2002
An innovative multivariate analysis revealed marked heterogeneity in binding profiles of antiparkinson agents at diverse receptors implicated in the etiology and/or treatment of Parkinson's disease.
Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors
- Biology, ChemistryNaunyn-Schmiedeberg's Archives of Pharmacology
- 1999
The present data suggest that roxindole activates mainly D3 vs. D2 or D4 receptors and 5-HT1A vs. 5- HT1B or 5,HT1D receptors, and Activation of D3 and/or 5-ht1A receptors may contribute to its potential antidepressant properties.
Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy.
- Biology, ChemistryThe Journal of pharmacology and experimental therapeutics
- 1995
Data demonstrate that the novel naphthofurane, (+)-S 14297, is a selective ligand (antagonist) at dopamine D3 receptors and suggest that their activation mediates hypothermia in the rat.
Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors.
- Biology, ChemistryEuropean journal of pharmacology
- 1995
Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells
- Biology, ChemistryBritish journal of pharmacology
- 1999
The results show that ropinirole is a full agonist at human D2, D3 and D4 dopamine receptors, and at least 10 fold selective for the human dopamine D3 receptor over the other D2 receptor family members.
Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors.
- Biology, ChemistryEuropean journal of pharmacology
- 1999
S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine.
- Biology, PsychologyThe Journal of pharmacology and experimental therapeutics
- 2000
Through activation of alpha(2)-ARs, S18616 potently inhibits corticolimbic adrenergic, serotonergic, and (frontocortical) dopaminergic transmission in parallel with the expression of its anxiolytic and sedative properties.
Dopamine D2 receptor-mediated G-protein activation in rat striatum: functional autoradiography and influence of unilateral 6-hydroxydopamine lesions of the substantia nigra
- Biology, PsychologyBrain Research
- 2001
Characterization of dopaminergic compounds at hD2short, hD4.2 and hD4.7 receptors in agonist-stimulated [35S]GTPγS binding assays
- Biology, PsychologyNaunyn-Schmiedeberg's Archives of Pharmacology
- 2000
It is suggested that therapeutic distinctions between typical and atypical antipsychotic drugs cannot be made based on their function at D2short, D4.2 and D 4.7 subtypes of dopamine receptors.
Agonist action at D2(long) dopamine receptors: ligand binding and functional assays
- Biology, ChemistryBritish journal of pharmacology
- 1998
There was no clear relation betwen the ability of an agonist to stabilize the formation of the ternary complex of agonist/receptor/G‐protein and the maximal activity of the agonist or the amplification factor.